Founded with a mission to revolutionize biomarker discovery, Sapient utilizes next-generation mass spectrometry and biocomputational analysis to identify and validate circulating biomarkers of health, disease, and drug response. The company focuses on enhancing the alignment of patients, disease biology, and specific therapies through its advanced platform. Sapient offers services in discovery metabolomics and lipidomics, targeted metabolite and lipid panels, discovery proteomics, and targeted proteomics, catering primarily to drug development, population health, and disease research markets.

Sapient's notable affiliates include leading experts in biotechnology and computational biology. The company has attracted significant investment from prominent venture capital firms in the life sciences sector. Key achievements include the rapid identification of critical biomarkers that have advanced understanding in various therapeutic areas. Sapient's impact is evident in its contribution to precision medicine, enabling more effective and personalized treatment strategies.